EvidencePublic signals only

Current public signals, separated from future ambition

This page organizes public milestones without implying unsupported clinical or regulatory claims.

TIPSKODITASTRO

Public proof items

Milestone stages

Latest public year

2025

Evidence policy

The page stays useful only if public fact and future ambition remain clearly separated.

Evidence is presented as proof of activity and visibility, not as a substitute for undisclosed clinical, regulatory, or commercial claims.

What this page does

LaunchesFundingProgramsOperationsConference

Organizes launches, funding, programs, operations, and conference participation into a factual trust layer.

What this page avoids

ClinicalRegulatoryCommercialUndisclosed

Unsupported claims around approvals, clinical outcomes, installed base, revenue, or market share.

What this page does

LaunchesFundingProgramsOperationsConference

Organizes launches, funding, programs, operations, and conference participation into a factual trust layer.

What this page avoids

ClinicalRegulatoryCommercialUndisclosed

Unsupported claims around approvals, clinical outcomes, installed base, revenue, or market share.

Signal library

What the extracted site materials already support

Each item is limited to public milestones surfaced in the current website materials.

2021.04

Completed

Company

Company founded by medical physics experts

RaphaRAD Inc. was founded in April 2021 with a team grounded in medical physics and radiation oncology.

2021.09

Completed

Funding

AC Partners investment secured

RaphaRAD secured investment from AC Partners, marking its first institutional funding milestone.

2021.11

Completed

Program

Selected for the TIPS program

RaphaRAD was selected for the Tech Incubator Program for Startups (TIPS).

2022.03

Completed

Product

LIM product launch

The LINAC QA solution LIM was publicly announced as launched in 2022.

2023.04

Completed

Product

BIM product launch

The brachytherapy QA solution BIM was publicly announced as launched in 2023.

2024.04

Completed

Program

Selected for the First Penguin Program

RaphaRAD was selected for the First Penguin Program administered by Korea Credit Guarantee Fund (KODIT).

2024.11

Completed

Program

Technology transfer from National Cancer Center

RaphaRAD completed a technology transfer agreement with the National Cancer Center (NCC), Korea.

2025.01

Completed

Company

Jeonju branch office established

RaphaRAD opened a branch office in Jeonju, Jeollabuk-do, expanding its operational footprint.

2025.12

Completed

Funding

Japan distribution agreement with Anzai Medical

RaphaRAD signed a distribution agreement with Anzai Medical Co., Ltd. to enter the Japanese market.

2025.09

Completed

Event

ASTRO participation and ongoing visibility

RaphaRAD has continued to participate in ASTRO, including the 2025 annual meeting.

Research updates

A separate feed for research-facing activity makes fast updates manageable

Conference visibility, R&D selections, and future research milestones are surfaced in one section instead of being buried inside general company news.

Update structure

This section is designed for frequent additions. New research-facing items can be appended in the dedicated research update source without redesigning the page.

Conference2025.09

ASTRO2025Visibility

ASTRO 2025 participation

Public conference participation keeps the company visible inside the radiation-oncology community and provides a recurring research-facing signal.

R&D project2024.11

JeonbukBio R&DProgram

Jeonbuk Advanced Bio R&D Project selection

This item signals externally visible participation in a named advanced-bio R&D program rather than a generic corporate update.

Conference2024.09

ASTRO2024Clinical

ASTRO 2024 participation

Repeated ASTRO participation strengthens the interpretation that RaphaRAD is sustaining external research and clinical visibility over time.

Conference2023.10

ASTRO2023Research

ASTRO 2023 participation

This earlier conference entry provides historical depth for the company’s research-facing activity rather than leaving visibility signals concentrated in one year.

Milestones

Past, current, and future statements are intentionally separated

Completed milestones are kept apart from current operating signals and future placeholders.

Past milestones

Past

FoundedProgramsFunding

Established items that form the historical base of the company narrative.

2021Past

2021.042021.052021.11

RaphaRAD founded

Founded in 2021 and followed quickly by early investment and TIPS selection.

2022-2023Past

First QA product launches

LIM and BIM were publicly introduced as QA solutions for radiation therapy workflows.

Current signals

Current

ProductsOperationsVisibility

Operating-state milestones that explain where the company appears to be now.

2023-2024Current

TIPS TownJeonju

Operational and program expansion

Headquarters moved to TIPS Town, new programs were selected, and a Jeonju branch office was established.

2023-2025Current

ASTRO202320242025

Continued conference and market presence

ASTRO 2023, 2024, and 2025 participation anchors continued external visibility.

Forward placeholders

PlaceholderPublic proof pendingLimited scope

Future-facing sections that stay intentionally constrained until public support exists.

ForwardNext

Next public milestones

Future validation, partnership, and commercialization milestones will be added when they become publicly supportable.

This evidence page does not imply clinical outcomes, regulatory approvals, installed base, or revenue metrics beyond what is publicly supported.

Products